Comparison of intravitreal anti-VEGF drug and steroid in the treatment of uveitic macular edema
Phase 2
Recruiting
- Conditions
- Macular edema in uveitic eyes.Chorioretinal inflammation, unspecified
- Registration Number
- IRCT2016100930224N1
- Lead Sponsor
- Vice chancellor for research, Shiraz University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 60
Inclusion Criteria
patients with inactive uveitis, according to sun group classification, who had visual loss due to macular edema (diagnosed by optical coherence tomography (OCT)) and not responding to topical medication such as steroid.
Exclusion criteria included any other ophthalmic disease that causes macular edema (e.g. diabetes, venous occlusive diseases); any intraocular surgery within 3 months of injection; media opacity that hinders assessment of macula by OCT, prior vitrectomy; Glaucoma; ocular hypertension and monocularity.
Exclusion Criteria
Not provided
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Macular thickness. Timepoint: 3, 6 and 12 months after injection of drug. Method of measurement: Optical Coherence Tomography.
- Secondary Outcome Measures
Name Time Method Visual acuity. Timepoint: 3, 6 and 12 months after injection. Method of measurement: Snellen chart.